| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font

Show document Help

Title:Problematika dostopa bolnikov z redkimi boleznimi do zdravil sirote : magistrsko delo
Authors:ID Wagner, Klemen (Author)
ID Kraljić, Suzana (Mentor) More about this mentor... New window
Files:.pdf MAG_Wagner_Klemen_2026.pdf (1,35 MB)
MD5: 6B72B037D11A0A5B1B7B0CE1F10A9C93
 
Language:Slovenian
Work type:Master's thesis/paper
Typology:2.09 - Master's Thesis
Organization:PF - Faculty of Law
Abstract:Zdravljenje redkih bolezni je ena najhitreje razvijajočih se vej medicine. Čeprav prizadenejo največ 5 na 10.000 oseb v Evropski uniji, je v evropskem prostoru okrog 30 milijonov oseb z redkimi boleznimi. Zaradi redkosti njihovega pojavljanja predstavljajo poseben izziv zdravstvenim sistemom vseh držav, ki se morajo soočati z visokimi cenami zdravil za njihovo zdravljenje, nezadostnimi dokazi o njihovi učinkovitosti in nezadovoljenimi potrebami bolnikov. Dostopnost do zdravil za redke bolezni se med državami razlikuje, kar je pogojeno s proračuni držav ter umeščanjem in oblikovanjem cen teh zdravil. V Republiki Sloveniji je večina odobrenih zdravil za zdravljenje redkih bolezni v celoti krita iz javnih sredstev. Financiranje razvoja zdravila sirote je novost v slovenski zakonodaji, saj jo poznamo od 4. decembra 2024. S sprejemom novele ZZrID-B se je omogočilo sofinanciranje znanstvenih študij na področju zadnjih predkliničnih faz in klinične faze razvoja zdravil za redke bolezni, ki ustrezajo definiciji zdravila sirote in so namenjena naprednemu zdravljenju pediatrične populacije. Slovenska zakonodaja omogoča dostop do zdravila sirote še preden zdravilo sirote dobi dovoljenje za promet z zdravilom po centraliziranem postopku v treh primerih, tj. klinično preskušanje, sočutna uporaba in interventni uvoz zdravila sirote. Ti mehanizmi omogočajo bolnikom z redkimi boleznimi predčasen dostop do zdravila sirote, kar izboljšuje njihov zdravstveni položaj in lajša trpljenje.
Keywords:redka bolezen, zdravilo sirote, promet z zdravili, sočutna uporaba, klinično preskušanje, interventni uvoz, URS, ZZrID-B, ZZdr-2, Uredba 141/2000.
Place of publishing:Maribor
Place of performance:Maribor
Publisher:K. Wagner
Year of publishing:2026
Number of pages:1 spletni vir (1 datoteka PDF (58 str.))
PID:20.500.12556/DKUM-96733 New window
UDC:364.35:614.35(043.3)
COBISS.SI-ID:269972483 New window
Publication date in DKUM:27.02.2026
Views:161
Downloads:64
Metadata:XML DC-XML DC-RDF
Categories:PF
:
Copy citation
  
Average score:(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share



Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:27.01.2026

Secondary language

Language:English
Title:Access of patients with rare diseases to orphan drugs
Abstract:The treatment of rare diseases is one of the fastest-evolving branches of medicine. Although they affect no more than 5 in 10,000 individuals in the European Union, there are approximately 30 million people living with rare diseases across Europe. Due to their low prevalence, they pose a unique challenge to national healthcare systems, which must contend with high drug prices, insufficient evidence regarding efficacy, and unmet patient needs. The accessibility of orphan drugs varies between countries, dictated by national budgets as well as reimbursement and pricing policies. In the Republic of Slovenia, the majority of approved drugs for the treatment of rare diseases are fully covered by public funds. The financing of orphan drug development is a recent addition to Slovenian legislation, introduced on 4 December 2024. The adoption of this legislative amendment enabled the co-financing of scientific studies in the final preclinical stages and the clinical development phases of drugs for rare diseases that meet the definition of an orphan drug and are intended for advanced therapy in the paediatric population. Slovenian legislation provides access to orphan drugs even before they receive marketing authorization via the centralized procedure in three specific cases: clinical trials, compassionate use, and the emergency importation of orphan drugs. These mechanisms give patients with rare diseases early access to treatment, thereby improving their clinical outcomes and alleviating suffering.
Keywords:rare disease, orphan drug, marketing of medicinal products, compassionate use, clinical trial, emergency import, Constitution of the Republic of Slovenia, ZZrID-B, ZZdr-2, Regulation (EC) No 141/2000.


Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica